Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has a novel mechanism of action offering the unique potential to address the unmet needs of chronic and severe health conditions. We plan to advance inhaled pravibismane in Phase 1 clinical development to treat chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Topical/local pravibismane is in Phase 2 development for the treatment of chronic wounds and orthopedic infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants. The FDA has granted pravibismane with Orphan Drug, Fast Track, and QIDP designations. Pravibismane is potent against a broad spectrum of pathogens, including Gram -positive and Gram -negative bacteria, fungal pathogens, and multidrug-resistant priority pathogens or “superbugs” identified by the US CDC. Furthermore, pravibismane has an unprecedented ability to prevent and eradicate microbial biofilms that contribute to resistance and chronic disease. Microbion’s site-specific delivery approach enables greater efficacy by achieving a higher therapeutic concentration of drug at the site of infection, improved safety, and a lower risk of developing antibiotic resistance associated with systemic antibiotic administration.
